company background image
NOX logo

Noxopharm CHIA:NOX Stock Report

Last Price

AU$0.091

Market Cap

AU$26.6m

7D

-8.1%

1Y

9.6%

Updated

02 Jan, 2025

Data

Company Financials

Noxopharm Limited

CHIA:NOX Stock Report

Market Cap: AU$26.6m

NOX Stock Overview

A biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. More details

NOX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings have declined by 9.5% per year over past 5 years

Does not have a meaningful market cap (A$27M)

Does not have meaningful revenue (A$2M)

Volatile share price over the past 3 months compared to the Australian market


My Notes

Capture your thoughts, links and company narrative

Noxopharm Limited Competitors

Alterity Therapeutics

ASX:ATH

AU$47.9m

Cynata Therapeutics

ASX:CYP

AU$43.4m

Medlab Clinical

ASX:MDC

AU$15.1m

Biotron

ASX:BIT

AU$16.2m

Price History & Performance

Summary of share price highs, lows and changes for Noxopharm
Historical stock prices
Current Share PriceAU$0.091
52 Week HighAU$0.14
52 Week LowAU$0.053
Beta0.74
1 Month Change-9.00%
3 Month Change-13.33%
1 Year Change9.64%
3 Year Change-77.25%
5 Year Change-66.30%
Change since IPO-50.81%

Recent News & Updates

Recent updates

Shareholder Returns

NOXAU BiotechsAU Market
7D-8.1%0.5%-0.09%
1Y9.6%3.4%8.3%

Return vs Industry: NOX exceeded the Australian Biotechs industry which returned 4.2% over the past year.

Return vs Market: NOX exceeded the Australian Market which returned 7.4% over the past year.

Price Volatility

Is NOX's price volatile compared to industry and market?
NOX volatility
NOX Average Weekly Movement12.0%
Biotechs Industry Average Movement9.8%
Market Average Movement7.9%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market3.0%

Stable Share Price: NOX's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: NOX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2015n/aGisela Mautnerwww.noxopharm.com

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types.

Noxopharm Limited Fundamentals Summary

How do Noxopharm's earnings and revenue compare to its market cap?
NOX fundamental statistics
Market capAU$26.59m
Earnings (TTM)-AU$3.58m
Revenue (TTM)AU$2.40m

11.1x

P/S Ratio

-7.4x

P/E Ratio

Is NOX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOX income statement (TTM)
RevenueAU$2.40m
Cost of RevenueAU$2.94m
Gross Profit-AU$534.81k
Other ExpensesAU$3.04m
Earnings-AU$3.58m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.012
Gross Margin-22.28%
Net Profit Margin-149.07%
Debt/Equity Ratio0%

How did NOX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 01:31
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Noxopharm Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution